Illumina, Inc. (NASDAQ:ILMN) Given Average Rating of “Hold” by Brokerages

Shares of Illumina, Inc. (NASDAQ:ILMN) have been given an average rating of “Hold” by the eighteen ratings firms that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, ten have given a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $129.6875.

A number of research analysts have commented on ILMN shares. UBS Group reiterated a “neutral” rating and issued a $135.00 price objective on shares of Illumina in a research report on Friday, February 6th. Evercore set a $150.00 price objective on Illumina in a research report on Friday, February 6th. Guggenheim increased their price objective on Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Piper Sandler decreased their price objective on Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a research report on Monday, February 9th. Finally, Robert W. Baird set a $137.00 price objective on Illumina in a research report on Friday, February 6th.

Illumina Stock Performance

ILMN stock opened at $134.50 on Wednesday. The business has a fifty day moving average price of $123.81 and a 200 day moving average price of $124.95. Illumina has a fifty-two week low of $69.83 and a fifty-two week high of $155.53. The stock has a market capitalization of $20.43 billion, a price-to-earnings ratio of 24.68, a P/E/G ratio of 2.58 and a beta of 1.49. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.08 and a quick ratio of 1.72.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, beating analysts’ consensus estimates of $1.26 by $0.09. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.10 billion. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The business’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period last year, the company earned $0.95 EPS. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Analysts expect that Illumina will post 4.51 EPS for the current fiscal year.

Insider Buying and Selling

In other Illumina news, SVP Patricia Leckman sold 2,370 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the transaction, the senior vice president directly owned 16,321 shares in the company, valued at approximately $1,896,173.78. This trade represents a 12.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.17% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ILMN. JPMorgan Chase & Co. boosted its position in shares of Illumina by 17.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 832,690 shares of the life sciences company’s stock worth $79,081,000 after purchasing an additional 124,246 shares during the last quarter. Generali Asset Management SPA SGR boosted its position in shares of Illumina by 51.6% in the 3rd quarter. Generali Asset Management SPA SGR now owns 22,249 shares of the life sciences company’s stock worth $2,113,000 after purchasing an additional 7,574 shares during the last quarter. Aaron Wealth Advisors LLC boosted its position in shares of Illumina by 342.6% in the 3rd quarter. Aaron Wealth Advisors LLC now owns 10,476 shares of the life sciences company’s stock worth $995,000 after purchasing an additional 8,109 shares during the last quarter. Elo Mutual Pension Insurance Co bought a new position in shares of Illumina in the 3rd quarter worth $2,319,000. Finally, Douglas Lane & Associates LLC boosted its position in shares of Illumina by 6.6% in the 3rd quarter. Douglas Lane & Associates LLC now owns 307,609 shares of the life sciences company’s stock worth $29,214,000 after purchasing an additional 18,914 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.